ADVERTISEMENT
A person in a white shirt activates a nasal spray
Oxford-AstraZeneca Nasal COVID-19 Vaccine Falters in Clinical Trial
Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.
Oxford-AstraZeneca Nasal COVID-19 Vaccine Falters in Clinical Trial
Oxford-AstraZeneca Nasal COVID-19 Vaccine Falters in Clinical Trial

Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.

Researchers say they’re abandoning the project in its current form—one of several that aims to induce what’s known as mucosal immunity against SARS-CoV-2.

  1. Home
  2. Subjects
  3. AstraZeneca, microbiology

AstraZeneca, microbiology

an illustration of a blood vessel with clumped-together blood cells inside
Blood Clot Risk from COVID-19 Higher than After Vaccines: Study
Shawna Williams | Apr 16, 2021 | 3 min read
The chance of developing cerebral venous sinus thrombosis was nearly 10 times higher in the two weeks following a diagnosis of SARS-CoV-2 infection than after receiving an mRNA vaccine, a data analysis finds.
johnson & johnson johnson&johnson j&j janssen covid-19 vaccine vaccination pandemic adenovirus vector blood clot side effect cerebral venous sinus thrombosis CVST sars-cov-2 coronavirus pandemic astrazeneca
US Health Authorities Ask for Pause in J&J COVID-19 Vaccination
Kerry Grens | Apr 13, 2021 | 2 min read
The FDA and CDC are investigating a handful of reports of blood clots that occurred several days after people received the one-and-done shot.
Blood Clots a Very Rare Side Effect of AstraZeneca Vaccine: EMA
Catherine Offord | Apr 8, 2021 | 2 min read
The European Medicines Agency emphasizes that the benefits of the jab in protecting against COVID-19 still far outweigh the risks.
oxford astrazeneza covid-19 vaccine sars-cov-2 coronavirus pandemic clinical trial phase 2 US chile peru hospitalization
AstraZeneca’s COVID-19 Shot Completely Prevented Severe Disease
Kerry Grens | Mar 22, 2021 | 2 min read
The vaccine was 79 percent effective at blocking symptomatic infections, according to data from a Phase 3 trial in the US, Chile, and Peru. A US safety oversight board says the data might be incomplete.
AstraZeneca, University of Oxford, vaccine, COVID-19, SARS-CoV-2, pandemic, coronavirus, vaccination, safety, Europe
Oxford/AstraZeneca COVID-19 Vaccine on Hold in Some Countries
Asher Jones | Mar 12, 2021 | 2 min read
Rollouts of the shot have ground to a halt following reports of blood clots, but health authorities say that these fears are unfounded and vaccination programs should continue.
COVID-19, SARS-CoV-2, coronavirus, pandemic, vaccine, vaccine trials, combination, mix and match, immunity, antibodies, T cells, Pfizer, Moderna, AstraZeneca, clinical trials
COVID-19 Vaccine Combos Aim to Boost Immunity
Asher Jones | Mar 9, 2021 | 6 min read
Mix-and-match shots could simplify vaccine rollout and stimulate more-robust immune responses. Ongoing clinical trials will soon give answers.
ADVERTISEMENT
ADVERTISEMENT